Is SDZNY a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Sandoz Group AG (SDZNY) rests on Biosimilar growth and the Bio100 plan: Biosimilar sales grew 20% at constant currencies in the first half of 2026 and 22% in the second quarter, with every region contributing. The bear case rests on price erosion is the constant risk in generics. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Sandoz Group AG makes off-patent medicines: generics, which copy small-molecule drugs once their patents expire, and biosimilars, which are near-copies of complex biologic drugs such as antibodies. It sells about 1,300 medicines, from antibiotics and cough remedies to cancer and immunology treatments, and employs more than 20,000 people. Net sales were $11.1B in 2025. In the first half of 2026 net sales were $5.76B, up 5% at constant currencies: generics brought in $3.89B (67%) and biosimilars $1.88B (33%, up from 29% a year earlier). By region, Europe is the core at $3.13B (54% of first-half sales), followed by International at $1.34B and North America at $1.30B, which was the fastest-growing region at +15% at constant currencies. The ten largest medicines grew 14% combined and made up 35% of sales. The company traces its roots to 1886, when the chemical firm Kern & Sandoz was founded in Basel. Sandoz merged with Ciba-Geigy in 1996 to form Novartis, which later used the Sandoz name for its generics arm. In 2006 Sandoz won approval for Omnitrope (somatropin), the world's first approved biosimilar. Novartis spun Sandoz off on October 4, 2023, giving shareholders one Sandoz share for every five Novartis shares, and Sandoz listed on the SIX Swiss Exchange under SDZ. It joined Switzerland's blue-chip SMI index on September 21, 2026. Recent deals include the December 2025 purchase of Just-Evotec Biologics EU, a biosimilar development and manufacturing site in France, for $274M, and an agreement with Samsung Bioepis for up to five biosimilar assets, including vedolizumab. Richard Saynor is CEO and Gilbert Ghostine chairs the board. Because the shares were distributed to Novartis's broad investor base, there is no controlling shareholder. US investors can hold the company through SDZNY, a sponsored Level I American Depositary Receipt program with J.P. Morgan as depositary, quoted on the OTCQX market. Each ADR represents one ordinary share, so the ADR price tracks the Swiss franc share price converted into dollars. Dividends are declared in Swiss francs and paid to ADR holders in dollars after Switzerland's 35% withholding tax, part of which US holders can generally reclaim under the US-Swiss tax treaty. The investment case is a mix shift. Generics are a high-volume business where prices fall every year; Sandoz now expects overall pricing to drop by a mid-single-digit percentage in 2026. Biosimilars carry better margins, and Sandoz is putting money behind them, including new plants in Slovenia. Core EBITDA rose 15% in dollars to $1.21B in the first half of 2026, a 20.9% margin, and core diluted earnings per share rose 17% to $1.71. Reported net income fell to $109M from $377M because of $470M of legal expenses tied to old US generic-pricing antitrust cases. Net debt was $3.55B at the end of June 2026, and the market value is about $37B at ~$84 per ADR.

The bull case for SDZNY

1. Biosimilar growth and the Bio100 plan

Biosimilar sales grew 20% at constant currencies in the first half of 2026 and 22% in the second quarter, with every region contributing. At its Capital Markets Day in London on September 8, 2026, Sandoz set out a program it calls Bio100: growing from 13 marketed biosimilars to more than 100 by 2040, and covering about 80% of biologic loss-of-exclusivity value from 2035, up from roughly 50% today. The pipeline stood at 36 assets after four new in-house programs were added in the first half (sotatercept, polatuzumab vedotin, burosumab and anifrolumab). Management said it expects biosimilars to become the majority of sales. The ambition is long-dated, and most of the drugs it targets still have years of patent protection left.

2. North America and the denosumab launch

North America is Sandoz's smallest region but its fastest grower, up 15% at constant currencies in the first half of 2026 and 18% in the second quarter. Biosimilar sales there rose 47%, driven mainly by Wyost and Jubbonti, its biosimilars of the bone drugs Xgeva and Prolia (denosumab), launched in June 2025. Sandoz says it moved from third to second place in North American gross sales of generics and biosimilars, based on IQVIA data for March 2026. As the June 2025 launch anniversary passes, comparisons get tougher and other denosumab biosimilars compete for the same patients. North American generics grew a modest 1% as new launches offset competition on paclitaxel.

3. Margin targets to 2030 and 2035

Sandoz guides 2026 net sales growth in the mid-to-high single digits at constant currencies and core EBITDA margin expansion of about 100 basis points. At the September 2026 Capital Markets Day it added a 2025 to 2030 outlook of mid-to-high single-digit annual sales growth and a core EBITDA margin of 25% to 27% by 2030, and reaffirmed its earlier mid-term outlook to 2028. Its 2035 ambition is to more than double 2025 net sales and reach a core EBITDA margin above 30%, excluding any GLP-1 effect. The first-half 2026 margin of 20.9% shows the distance still to cover. The levers named are a richer sales mix, cost-price savings in manufacturing and operating leverage.

4. GLP-1 generics

Copies of semaglutide and tirzepatide, the active ingredients in Ozempic, Wegovy, Mounjaro and Zepbound, are a large potential market as patents expire country by country. In July 2026 Brazil's regulator approved Owozy, Sandoz's first GLP-1 medicine, which it will sell there with partner Adalvo. In June 2026 the US FDA accepted two Sandoz applications for generic tirzepatide autoinjectors for review. Sandoz expects no material contribution from generic semaglutide in 2026, and its 2035 ambition excludes GLP-1s, so any success here would come on top of stated targets. The European Commission also approved its insulin lispro and insulin aspart biosimilars in the period.

5. Capital spending and cash flow

Sandoz is building out its own biosimilar manufacturing rather than relying on partners. Capital spending rose to $532M in the first half of 2026 from $310M, covering a drug-substance plant in Lendava, a fill-and-finish plant in Brnik and a development center in Ljubljana, all in Slovenia; analysts and investors are due to tour the sites on November 9 and 10, 2026. Operating cash flow still rose to $871M from $523M, and free cash flow rose to $337M from $207M. Management free cash flow, which strips out one-off items, held at $503M. Net debt was flat at $3.55B, even after paying a $440M dividend in April.

6. Closing out legacy US litigation

Since 2016 Sandoz Inc. has faced US investigations and lawsuits over alleged price-fixing of generic drugs between 2013 and 2015. It paid $195M in a 2020 resolution with the Department of Justice Antitrust Division and settled earlier class actions. In 2026 it agreed to settle with a consortium of 43 US states and territories and with the indirect reseller class, which drove $470M of legal expenses in the first half. Once these settlements are completed, the company says only claims from plaintiffs who opted out of earlier class settlements will remain, and that the settlements do not change 2026 guidance or its mid-term outlook.

The bear case for SDZNY

Price erosion is the constant risk in generics. Sandoz raised its 2026 expectation for overall price decline to a mid-single-digit percentage, citing short-term market dynamics in Germany and strong North American biosimilar volumes that carry their own discounts, and first-half volume growth of 10% was offset by 5% price erosion. Biosimilar launches draw several rivals at once, so the denosumab gains may face tougher pricing as more competitors arrive. The anti-infectives business is exposed to Chinese penicillin ingredient makers, who cut global prices for key ingredients such as 6-APA after US tariffs in 2025 reduced their exports to the US; that hit first-quarter 2026 sales. Guidance excludes the possible effect of new US tariffs, and Sandoz manufactures heavily in Europe. Legal costs remain material: first-half 2026 reported net income was $109M against $750M of core net income, largely because of $470M in legal expenses, and opt-out antitrust claims are still pending. The heavy Slovenian build-out raises capital spending and execution risk before the plants contribute. Sandoz reports in dollars but earns more than half its sales in Europe and pays dividends in Swiss francs, so currency moves affect reported growth and what ADR holders receive. The 2030 and 2035 targets depend on regulators and courts letting biosimilars reach market on schedule, and long-range ambitions can slip. SDZNY itself trades over the counter, where volume is lower than on the SIX Swiss Exchange, and US holders lose part of each dividend to the 35% Swiss withholding tax unless they file a reclaim.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SDZNY already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on SDZNY

Too few analysts publish on SDZNY for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The SDZNY forecast page covers what coverage does exist.

How is SDZNY valued? (as of October 2026)

Price

$84.28

Market cap

$36.56B

P/E (TTM)

57.33

Forward P/E

18.12

Price / book

4.07

Beta

0.46

52-week range

$60.35 to $94.15

Snapshot for SDZNY as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Net sales (TTM to June 2026): ~$11.6B
Net sales (H1 2026): ~$5.76B (+5% at constant currencies)
Core EBITDA (H1 2026): ~$1.21B (20.9% margin)
Core diluted EPS (H1 2026): ~$1.71 (reported net income ~$109M)
Net debt: ~$3.55B (June 30, 2026)
Market cap: ~$37B (SDZNY ~$84, SDZ ~CHF 70)

Trailing sales of ~$11.6B (2025's $11.1B, less the first half of 2025, plus the first half of 2026) put the company at a bit over 3 times sales. The gap between core and reported earnings is wide this year: core net income was $750M in the first half against reported net income of $109M, with legal provisions, restructuring and separation costs making up most of the difference. Net debt of $3.55B is modest next to roughly $2.4B of annualized core EBITDA. The dividend of CHF 0.80 per share for 2025, up from CHF 0.60, works out to a yield of a little over 1% before Swiss withholding tax. Margin progress toward the 25% to 27% 2030 target is the main thing the valuation is waiting on.

How do you decide if SDZNY is a buy?

Rather than asking whether SDZNY is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold SDZNY indirectly through an index or sector ETF before adding more.

What would change your mind on SDZNY

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Biosimilar growth and the Bio100 plan stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: price erosion is the constant risk in generics fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the SDZNY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SDZNY against your real portfolio and see your actual exposure before deciding.

Investing in Sandoz Group AG with AI

Connect the broker you already use and ask Walnut's AI how SDZNY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does SDZNY fit me?

FAQ

Is SDZNY a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Biosimilar growth and the Bio100 plan, with core diluted eps (h1 2026) at ~$1.71 (reported net income ~$109M). The bear case rests on price erosion is the constant risk in generics. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell SDZNY?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Price erosion is the constant risk in generics. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

What is the bull case for SDZNY?

Biosimilar growth and the Bio100 plan. Biosimilar sales grew 20% at constant currencies in the first half of 2026 and 22% in the second quarter, with every region contributing.

What is the bear case for SDZNY?

What does Sandoz Group AG do?

Swiss maker of generic and biosimilar medicines, spun off from Novartis in 2023, selling about 1,300 off-patent drugs worldwide.

What would have to change for SDZNY to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Biosimilar growth and the Bio100 plan) stalling in the reported numbers rather than in the narrative, the risk above (price erosion is the constant risk in generics) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What is SDZNY?

SDZNY is the US ticker for Sandoz Group AG's American Depositary Receipts. Sandoz is a Swiss maker of generic and biosimilar medicines, listed in Zurich on the SIX Swiss Exchange as SDZ. The ADRs are quoted on the OTCQX market, with J.P. Morgan as depositary, and each ADR represents one ordinary Sandoz share.

What is the SDZNY ADR ratio?

The ratio is one to one: each SDZNY ADR represents one Sandoz ordinary share. The ADR price in dollars should therefore track the Swiss franc price of SDZ multiplied by the dollar-franc exchange rate, give or take small trading differences.

Does Sandoz pay a dividend?

Yes. Sandoz pays one dividend a year in Swiss francs after its spring annual meeting. The April 2026 meeting approved CHF 0.80 per share for 2025, up from CHF 0.60. ADR holders receive dollars after Switzerland's 35% withholding tax, and US holders can usually reclaim part of it under the US-Swiss tax treaty.

Walnut is informational, not investment advice, and gives no verdict on SDZNY. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.